2/3
09:06 pm
cytk
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
Low
Report
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
2/3
08:12 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
1/28
08:06 am
cytk
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
Low
Report
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
1/28
08:03 am
cytk
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
1/27
01:39 pm
cytk
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
Low
Report
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
1/27
10:07 am
cytk
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
Low
Report
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
1/27
08:00 am
cytk
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
Low
Report
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
1/27
07:30 am
cytk
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Low
Report
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
1/23
02:24 pm
cytk
The Future of Cardiovascular Care [Forbes]
Low
Report
The Future of Cardiovascular Care [Forbes]
1/22
02:39 pm
cytk
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
Low
Report
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
1/21
10:17 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.
1/21
09:08 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at B. Riley.
1/20
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/20
10:24 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $74.00. They now have an "overweight" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $74.00. They now have an "overweight" rating on the stock.
1/12
10:07 pm
cytk
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
Low
Report
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
1/9
12:02 pm
cytk
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/8
10:05 am
cytk
Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.
Low
Report
Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.
1/8
08:59 am
cytk
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
1/7
08:47 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
1/5
04:00 pm
cytk
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/2
09:05 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
12/30
09:57 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
12/22
05:36 pm
cytk
Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
Low
Report
Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
12/22
02:08 pm
cytk
Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.
12/22
01:07 pm
cytk
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.